Clinical trials: Stereotactic Body Radiotherapy
Centrally Located Hepatocellular Carcinoma, Stereotactic Body Radiotherapy
Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study
Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial…
- Conditions
- Centrally Located Hepatocellular Carcinoma, Stereotactic Body Radiotherapy, Hepatectomy
- Trial name
- NCT05598060
- Testing
- Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Prostate Cancer, Stereotactic Body Radiotherapy
A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer
Stereotactic body radiotherapy (SBRT) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(PCa).
- Conditions
- Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy
- Trial name
- NCT05430737
- Testing
- stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Head and Neck Squamous Cell Carcinoma, Metastases
Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)
To evaluate the safety and efficacy of combination of Sintilimab and SBRT on the basis of platinum-containing chemotherapy as the first-line treatment of limited metastatic head and neck squamous cell carcinoma (LM-HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastases, Immunotherapy, Stereotactic Body Radiotherapy
- Trial name
- LM-HNSCC (NCT05136768)
- Testing
- Sintilimab, SBRT, Platinum based chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun-Lin Yi, MD
Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombosis
Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis
Macrovascular invasion (MVI) is common in HCC, Portal vein tumor thrombus (PVTT) is the most common form of MVI in HCC, with an incidence ranging from 44 to 62.2%.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombosis, Stereotactic Body Radiotherapy
- Trial name
- NCT04966195
- Testing
- stereotactic body raiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Surgical Resection, Stereotactic Body Radiotherapy
Post SBRT Pulmonary Metastasectomy (PSPM) Trial
The goal of this study is to determine the effectiveness of SBRT on reducing tumor viability at a pathologic level and also to evaluate the effects of combined modality treatment on low volume pulmonary metastases, in hopes of…
- Conditions
- Surgical Resection, Stereotactic Body Radiotherapy, Lung Cancer, Pulmonary Metastasectomy
- Trial name
- PSPM (NCT04160143)
- Testing
- Surgical resection and stereotactic body radiation therapy (SBRT)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- McMaster University
Spinal Cord Compression, Cauda Equina Syndrome
Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression
Spinal cord compression (SCC) is a devastating complication of advanced malignancy, and can cause significant deterioration in function and quality of life (QoL).
- Conditions
- Spinal Cord Compression, Cauda Equina Syndrome, Stereotactic Body Radiotherapy
- Trial name
- CRUSSH (NCT03529708)
- Testing
- 3D CRT plus SBRT boost
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Juravinski Cancer Center
Breast Cancer, Recurrent Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor
- Trial name
- CLEAR (NCT03750396)
- Testing
- Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Hepatocellular Carcinoma, Hepatectomy
Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma
The prognosis of small liver cancer (≤5 cm) with stereotactic body radiotherapy (SBRT) is encouraging, the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, and 3-year overall…
- Conditions
- Hepatocellular Carcinoma, Hepatectomy, Stereotactic Body Radiotherapy
- Trial name
- NCT03609151
- Testing
- laparoscopic hepatectomy (surgery), stereotactic body radiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent Hepatocellular Carcinoma, Microwave Ablation
Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma
The prognosis of small liver cancer (≤5 cm) who had underwent stereotactic body radiotherapy (SBRT) is encouraging, with the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, 3-year…
- Conditions
- Recurrent Hepatocellular Carcinoma, Microwave Ablation, Stereotactic Body Radiotherapy
- Trial name
- NCT03609268
- Testing
- microwave ablation (MWA), stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer, Stereotactic Body Radiotherapy
Improving REsectability in Pancreatic NEoplasms (IRENE)
Evaluation of clinical response in terms of resectability of patients with locally advanced pancreatic cancer treated with neoadjuvant chemotherapy plus stereotactic body radiotherapy.
- Trial name
- IRENE (NCT03460925)
- Testing
- SBRT plus chemotherapy
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma, Cholangiocarcinoma
Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT01213758
- Testing
- Measuring liver function by PET/CT
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- University of Aarhus